These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 27695947)

  • 21. L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile.
    Kommoss FK; Karnezis AN; Kommoss F; Talhouk A; Taran FA; Staebler A; Gilks CB; Huntsman DG; Krämer B; Brucker SY; McAlpine JN; Kommoss S
    Br J Cancer; 2018 Aug; 119(4):480-486. PubMed ID: 30050154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MELF Pattern for Predicting Lymph Node Involvement and Survival in Grade I-II Endometrioid-type Endometrial Cancer.
    Sanci M; Güngördük K; Gülseren V; Karadeniz T; Kocaer M; Gungorduk O; Özdemir İA
    Int J Gynecol Pathol; 2018 Jan; 37(1):17-21. PubMed ID: 28319574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of estrogen receptor and L1 cell adhesion molecule expression on endometrial cancer outcome correlates with clinicopathological risk group and molecular subgroup.
    Aro K; Pasanen A; Bützow R; Loukovaara M
    Gynecol Oncol; 2024 Oct; 189():9-15. PubMed ID: 38972089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Asparaginase-like protein 1 as a prognostic tissue biomarker in clinicopathologically and molecularly characterized endometrial cancer.
    Loukovaara MJ; Huvila JK; Pasanen AM; Bützow RC
    Eur J Obstet Gynecol Reprod Biol; 2024 Sep; 300():23-28. PubMed ID: 38972163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The significance of L1CAM expression in clear cell carcinoma of the endometrium.
    Fadare O; Roma AA; Desouki MM; Gwin K; Hanley KZ; Jarboe EA; Liang SX; Quick CM; Zheng W; Hecht JL; Parkash V; Wang XJ
    Histopathology; 2018 Feb; 72(3):532-538. PubMed ID: 28941294
    [No Abstract]   [Full Text] [Related]  

  • 26. Prognostic significance of DNA topoisomerase II-alpha (Ki-S1) immunoexpression in endometrial carcinoma.
    Bildrici K; Tel N; Ozalp SS; Yalcin OT; Yilmaz V
    Eur J Gynaecol Oncol; 2002; 23(6):540-4. PubMed ID: 12556100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CXCL14-CXCR4 and CXCL12-CXCR4 Axes May Play Important Roles in the Unique Invasion Process of Endometrioid Carcinoma With MELF-Pattern Myoinvasion.
    Kojiro-Sanada S; Yasuda K; Nishio S; Ogasawara S; Akiba J; Ushijima K; Yano H
    Int J Gynecol Pathol; 2017 Nov; 36(6):530-539. PubMed ID: 28277316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lymphovascular space invasion (LVSI) is an isolated poor prognostic factor for recurrence and survival among women with intermediate- to high-risk early-stage endometrioid endometrial cancer.
    Weinberg LE; Kunos CA; Zanotti KM
    Int J Gynecol Cancer; 2013 Oct; 23(8):1438-45. PubMed ID: 24257558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The expression ratios of estrogen receptor α (ERα) to estrogen receptor β1 (ERβ1) and ERα to ERβ2 identify poor clinical outcome in endometrioid endometrial cancer.
    Zannoni GF; Monterossi G; De Stefano I; Gargini A; Salerno MG; Farulla I; Travaglia D; Vellone VG; Scambia G; Gallo D
    Hum Pathol; 2013 Jun; 44(6):1047-54. PubMed ID: 23266443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Expression and significance of immune checkpoint B7-homolog 4 in endometrial cancer].
    Zong LJ; Xiang Y; Yu SN; Lu ZH; Chen J; Huang WH
    Zhonghua Fu Chan Ke Za Zhi; 2022 Dec; 57(12):921-931. PubMed ID: 36562226
    [No Abstract]   [Full Text] [Related]  

  • 31. Prognostic significance of BAF57 expression in patients with endometrial carcinoma.
    Kagami S; Kurita T; Kawagoe T; Toki N; Matsuura Y; Hachisuga T; Matsuyama A; Hashimoto H; Izumi H; Kohno K
    Histol Histopathol; 2012 May; 27(5):593-9. PubMed ID: 22419023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study.
    Visser NCM; van der Putten LJM; van Egerschot A; Van de Vijver KK; Santacana M; Bronsert P; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Krakstad C; Tangen IL; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Hausnerova J; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Trovik J; Amant F; Massuger LFAG; Bulten J; Pijnenborg JMA
    Hum Pathol; 2019 Jul; 89():90-98. PubMed ID: 31054899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical value of immunohistochemically detected lymphovascular invasion in endometrioid endometrial cancer.
    Alexander-Sefre F; Singh N; Ayhan A; Thomas JM; Jacobs IJ
    Gynecol Oncol; 2004 Feb; 92(2):653-9. PubMed ID: 14766262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value and clinicopathologic characteristics of L1 cell adhesion molecule (L1CAM) in a large series of vulvar squamous cell carcinomas.
    Trietsch MD; Oonk MH; Hawinkels LJ; Bor R; van Eendenburg JD; Ivanova Z; Peters AA; Nijman HW; Gaarenstroom KN; Bosse T
    Oncotarget; 2016 May; 7(18):26192-205. PubMed ID: 27028855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.
    Edmondson RJ; Crosbie EJ; Nickkho-Amiry M; Kaufmann A; Stelloo E; Nijman HW; Leary A; Auguste A; Mileshkin L; Pollock P; MacKay HJ; Powell ME; Bosse T; Creutzberg CL; Kitchener HC
    Gynecol Oncol; 2017 Aug; 146(2):327-333. PubMed ID: 28511869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of L1CAM expression in addition to ProMisE in endometrial cancer.
    Kim J; Kim SI; Kim NR; Kim H; Kim HS; Chung HH; Kim JW; Lee C; Lee M
    Gynecol Oncol; 2023 Jul; 174():231-238. PubMed ID: 37236032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. p53, Pirh2, and L1CAM as Promising Prognostic Biomarkers of Endometrial Carcinoma: An Immunohistochemical and Genetic Study.
    Abdelrahman AE; Salem A; Al Attar AZ; Elsebai E; Samy W; Ibrahim MA; Ibrahim HM
    Appl Immunohistochem Mol Morphol; 2022 Nov-Dec 01; 30(10):713-725. PubMed ID: 36251972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The association of the microcystic, elongated and fragmented (MELF) invasion pattern in endometrial carcinomas with deep myometrial invasion, lymphovascular space invasion and lymph node metastasis.
    Dogan Altunpulluk M; Kir G; Topal CS; Cetiner H; Gocmen A
    J Obstet Gynaecol; 2015 May; 35(4):397-402. PubMed ID: 25279582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.
    Watari H; Todo Y; Takeda M; Ebina Y; Yamamoto R; Sakuragi N
    Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. L1CAM and HER2 Expression in Early Endometrioid Uterine Cancer.
    Abdel Azim S; Sprung S; Mutz-Dehbalaie I; Fessler S; Zeimet AG; Marth C
    Int J Gynecol Pathol; 2017 Jul; 36(4):356-363. PubMed ID: 28221216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.